VolitionRx Limited (NYSE:VNRX) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET
Company Participants
Scott Powell - Executive Vice President, Investor Relations
Cameron Reynolds - President and Group Chief Executive Officer
Terig Hughes - Group Chief Financial Officer
Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary
Andrew Retter - Medical Consultant, Volition
Louise Batchelor - Chief Marketing and Communications Officer
Conference Call Participants
Ross Osborn - Cantor Fitzgerald
Bruce Jackson - The Benchmark Company
Tim Moore - EF
Operator
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited Third Quarter 2023 Earnings Conference Call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator Instructions] This conference is being recorded today, November 15, 2023.
I’d now like to turn the conference call over to Scott Powell, Executive Vice President of Investor Relations. Please go ahead.
Scott Powell
Thank you and welcome, everyone to today's earnings conference call for VolitionRx Limited. This call will cover Volition's financial and operating results for the third quarter of 2023, along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question-and-answer session.
Also on our call today are Mr. Cameron Reynolds, President and Group Chief Executive Officer; Mr. Terig Hughes, Group Chief Financial Officer; Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary Subsidiary, and Dr. Andrew Retter Medical Consultant to Volition.
Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs, as well as assumptions we have
- Read more current VNRX analysis and news
- View all earnings call transcripts